Citadel Securities Starts Seattle Genetics (SGEN) at Reduce; Adcetris Approvable, But Market Opportunity Appears Overestimated

Go back to Citadel Securities Starts Seattle Genetics (SGEN) at Reduce; Adcetris Approvable, But Market Opportunity Appears Overestimated